{"schema_version":"1","generated_at":"2026-11-14T01:03:14.453Z","data_as_of":null,"url":"https://www.findmykol.com/kol/oluchi-oke","json_url":"https://www.findmykol.com/kol/oluchi-oke/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"oluchi-oke","name":"Oluchi Oke","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"The University of Texas MD Anderson Cancer Center","institution_url":"https://www.findmykol.com/institution/the-university-of-texas-md-anderson-cancer-center","city":"Houston","state":"TX","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"}},"identifiers":{"npi":"1124463211","orcid":"0000-0003-0464-8317","openalex":"A5023933444"},"summary":"Oluchi Oke is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 28 publications with 219 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":28,"cited_by_count":219,"h_index":7,"latest_activity_year":2026,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06318897","title":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"M.D. Anderson Cancer Center","source_url":"https://clinicaltrials.gov/study/NCT06318897","trial_url":"https://www.findmykol.com/trial/NCT06318897"}],"source":"trials"},"payments":{"company_count":8,"program_years":{"first":2021,"last":null},"rows_total":14,"shown":3,"withheld":11,"rows":[{"payer":"Merck & Co.","program_year":2025,"amount_usd":1983450.76,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1124463211"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":225.98,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1124463211"},{"payer":"PUMA BIOTECHNOLOGY, INC.","program_year":2025,"amount_usd":124.48,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1124463211"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1124463211","source":"payments"},"prescribing":{"data_year":2024,"areas_total":4,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":77.6,"classes_total":3,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":48.3,"drugs":[{"name":"Anastrozole","share_pct":73.9},{"name":"Exemestane","share_pct":14.8},{"name":"Letrozole","share_pct":11.3}],"max_beneficiaries":null},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":20.7,"drugs":[{"name":"Verzenio","share_pct":60.7},{"name":"Ibrance","share_pct":39.3}],"max_beneficiaries":null}]},{"area":"Nervous system","share_pct":10.9,"classes_total":2,"classes":[{"class":"Gabapentinoids","setting":"prescribed","share_pct":7.1,"drugs":[{"name":"Gabapentin","share_pct":100}],"max_beneficiaries":null},{"class":"Phenothiazine","setting":"prescribed","share_pct":3.7,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":7.8,"classes_total":1,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":7.8,"drugs":[{"name":"Ondansetron Hcl","share_pct":100}],"max_beneficiaries":15}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":28,"shown":5,"withheld":23,"matched_by":"OpenAlex author record","recent":[{"title":"Real-world pregnancy outcomes following temporary interruption of adjuvant endocrine therapy in early-stage hormone receptor–positive breast cancer.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e12702","status":"verified"},{"title":"Abstract PD7-03: Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer","year":2026,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs25-pd7-03","status":"verified"},{"title":"Phase II study of olaparib plus ATR inhibitor ceralasertib in patients with metastatic breast cancer and germline BRCA1/2 pathogenic variants who progressed on prior PARP inhibitor therapy.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.1142","status":"verified"},{"title":"Complication Rates are Low After Invasive Procedures on the Lactating Breast in Patients Treated for Breast Cancer During Pregnancy","year":2025,"journal":"Annals of Surgical Oncology","source_url":"https://doi.org/10.1245/s10434-025-17856-y","status":"verified"},{"title":"ASO Visual Abstract: Complication Rates Are Low After Invasive Procedures on the Lactating Breast in Patients Treated for Breast Cancer During Pregnancy","year":2025,"journal":"Annals of Surgical Oncology","source_url":"https://doi.org/10.1245/s10434-025-18064-4","status":"verified"}],"source":"works"},"contact":{"address_1":"1515 HOLCOMBE BLVD UNIT 463","address_2":"DIVISION OF CANCER MEDICINE","city":"Houston","state":"TX","zip":"770304000","phone":"713-792-7246","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1124463211","source":"identity"},"similar":[{"name":"Hagop Kantarjian","slug":"hagop-kantarjian","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/hagop-kantarjian","json_url":"https://www.findmykol.com/kol/hagop-kantarjian/profile.json"},{"name":"Gabriel Hortobagyi","slug":"gabriel-hortobagyi","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/gabriel-hortobagyi","json_url":"https://www.findmykol.com/kol/gabriel-hortobagyi/profile.json"},{"name":"Anil Sood","slug":"anil-sood","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/anil-sood","json_url":"https://www.findmykol.com/kol/anil-sood/profile.json"},{"name":"Jaffer Ajani","slug":"jaffer-ajani","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jaffer-ajani","json_url":"https://www.findmykol.com/kol/jaffer-ajani/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":11,"publications":23}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2018-03-17","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}